论文部分内容阅读
目的通过分析广泛期小细胞肺癌(SCLC)患者治疗前乳酸脱氢酶(LDH)和神经元特异性烯醇化酶(NSE)与无进展生存(PFS)和总生存(OS)的关系,探讨其是否为影响广泛期SCLC患者的疗效预测和预后的因素。方法本研究回顾性地分析了2008年3月至2014年9月于中国医科大学附属第一医院肿瘤内科住院治疗的广泛期SCLC患者83例。用Kaplan-Meier方法和Cox比例风险模型分析患者治疗前LDH和NSE与PFS和OS的关系,P<0.05为差异有统计学意义。结果治疗前LDH水平与患者PFS(P=0.001)及OS(P=0.036)均显著相关,治疗前NSE水平与患者PFS(P=0.007)及OS(P=0.013)也显著相关。结论LDH和NSE是影响广泛期SCLC患者疗效的预测因素和影响生存的预后因素。
Objective To investigate the relationship between the levels of lactic dehydrogenase (LDH), neuron specific enolase (NSE) and progression-free survival (PFS) and overall survival (OS) in patients with extensive stage small cell lung cancer (SCLC) Whether it affects the prognosis and prognosis of patients with extensive SCLC. Methods This study retrospectively analyzed 83 patients with extensive-term SCLC who were hospitalized for oncology in the First Affiliated Hospital of China Medical University from March 2008 to September 2014. Kaplan-Meier method and Cox proportional hazards model analysis of patients before treatment LDH and NSE and PFS and OS, P <0.05 for the difference was statistically significant. Results The level of LDH before treatment was significantly correlated with both PFS (P = 0.001) and OS (P = 0.036). The level of NSE before treatment was also significantly correlated with PFS (P = 0.007) and OS (P = 0.013). Conclusion LDH and NSE are prognostic factors influencing the curative effect of patients with extensive stage SCLC and prognostic factors of survival.